Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus

Hypertension Research

Volumn 31, Issue 1, 2008, Pages 43-50

  Fogari, Roberto ^a   Derosa, Giuseppe ^a   Zoppi, Annalisa ^a   Rinaldi, Andrea ^a   Preti, Paola ^a   Lazzari, Pierangelo ^a   Mugellini, Amedeo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Delapril; Diabetic hypertensives; Hydrochlorothiazide; Manidipine; Olmesartan

Indexed keywords

ANTIDIABETIC AGENT; DELAPRIL; ELECTROLYTE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; MANIDIPINE; OLMESARTAN; PLACEBO; POTASSIUM; TRIACYLGLYCEROL; URIC ACID;

AGED; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECUMBENCY; SITTING; STANDING; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIHYDROPYRIDINES; DIURETICS; DRUG COMBINATIONS; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPOTENSION, ORTHOSTATIC; IMIDAZOLES; INDANS; MALE; POSTURE; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 40149087517     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.43     Document Type: Article

References (55)

1. European Society of Hypertension-European Society of Cardiology Guidelines Committee: 2003 guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
2. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.
3. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
4. Hansson L, Zanchetti A, Carruthers SG, et al: Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351:1755-1762.
5. JATOS Study Group: The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients QATOS): protocol, patient characteristics and blood pressure during the first 12 months. Hypertens Res 2005; 28: 513-520.
6. Sowers JR: Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003; 16: 41S-45S.
7. Ichihara A, Hatashi M, Hirota N, et al: Angiotensin II type 2 receptor inhibits prorenin processing in juxtaglomerular cells. Hypertens Res 2003; 26: 915-921.
8. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
9. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of iftsartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
10. Saruta T, Nishikawa K: Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am J Hypertens 1991; 4: 23S-28S.
11. Cheer SM, McClellan K: Manidipine: a review of its use in hypertension. Drugs 2001; 61: 1777-1799.
12. Toba H, Shimizu T, Miki S, et al: Calcium channel blockers reduce angiotensin II-induced superoxide generation and inhibit lectin-like oxidized low-density lipoprotein receptor-1 expression in endothelial cells. Hypertens Res 2006; 29: 105-116.
13. Fogari R, Zoppi A, Lusardi P, et al: Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 ing once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randornized, parallel group, placebo-controlled study. Blood Press Suppl 1996; 5: 16-23.
14. Fogari R, Zoppi A, Mugellini A, et al: Efficacy of delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Adv Ther 1997; 14: 254-261.
15. Mancia G, Omboni S, Agabiti-Rosei E, et al: Antihypertensive efficacy of manidipine and enalapril in hypertensive diabetic patients. J Cardiovasc Pharmacol 2000; 35: 926-931.
16. Omboni S, Fogari R, Mancia G: A smooth blood pressure control is obtained over 24 h by delapril in mild to moderate essential hypertensives. Blood Press 2001; 10: 170-175.
17. Hatta T, Nakata T, Harada S, et al: Lowering of blood pressure improves endothelial dysfunction by increase of nitric oxide production in hypertensive rats. Hypertens Res 2002; 25: 455-460.
18. Mugellini A, Dobovisek J, Planinc D, Cremonesi G, Fogari R: Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Clin Ther 2004; 26: 1419-1426.
19. Mugellini A, Vaccarella A, Celentano A, Scanferla F, Zoppi A, Fogari R: Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press Suppl 2005; 1: 6-13.
20. Mizuno M, Sada T, Ikeda M, et al; Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181-188.
21. Agata J, Ura N, Yoshida H, et al: Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin converting enzyme. Hypertens Res 2006; 29: 865-874.
22. Stumpe KO, Ludwig M: Antihypertensive efficacy of olmesartan compared with other antibypertensive drugs. J Hum Hypertens 2002; 16 (Suppl 2): S24-S28.
23. Imai E, Haneda M, Chan JCN, Makino H, for the ORIENT Investigators: Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT): rationale and study design. Hypertens Res 2006; 29: 703-709.
24. Sellin L, Stegbauer J, Laeis P, Rump LC: Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23: 2083-2092.
25. Rump LC, Ambrosioni E, Burnier M, Horl W, Rabelink AJ: Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006; 20: 299-301.
26. Maser RE, Lenhard MJ: Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 2005; 90: 5896-5903.
27. Turnheim K: Drug therapy in the elderly. Exp Gerontol 2004; 39: 1731-1738.
28. Moriguchi K, Rakugi H, Nakata S, et al: Impairment of instantaneous autonomic regulation relates to blood pressure fall immediately after standing in the elderly and hypertensives. Hypertens Res 2006; 29: 557-566.
29. WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ Tech Rep Ser 1980; 646: 1-80.
30. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26: S5-S20.
31. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
32. Bunn HF, Gabbay KH, Gallop PM: The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978; 200: 21-27.
33. Klose S, Borner K: Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem 1978; 15: 121-130.
34. Wahlefeld AW: Triglycerides determination after enzymatic hydrolysis, in Bergmeyer HU (ed): Methods of Enzymatic Analysis, 2nd English ed. New York, Academic Press, 1974, pp 18-31.
35. Havel RJ, Eder HA, Bragdon JH: The distribution and chemical composition of ultracentrifugally separated lipo-proteins in human serum. J Clin Invest 1955; 34: 1345-1353.
36. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
37. Masaki KH, Schatz IJ, Burchfiel CM, et al: Orthostatic hypotension predicts mortality in elderly men. The Honolulu Heart Program. Circulation 1998; 98: 2290-2295.
38. Rutan GH, Hermanson B, Bild DE, et al: Orthostatic hypotension in older adults: the Cardiovascular Health Study. Hypertension 1992; 19: 508-519.
39. Wu JS, Lu FH, Yang YC, et al: Postural hypotension and postural dizziness in patients with non-insulin dependent diabetes. Arch Intern Med 1999; 159: 1350-1356.
40. Christlieb AR, Munichoodappa C, Braaten JT: Decreased response of plasma renin activity to orthostasis in diabetic patients with orthostatic hypotension. Diabetes 1974; 23: 835-841.
41. Mathias CJ, Kimber JR: Postural hypotension: causes, clinical features, investigation and management. Annu Rev Med 1999; 50: 317-336.
42. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology: Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Neurology 1996; 46: 1470.
43. Wilson IM, Freis ED: Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effects of chlorothiazide. Circulation 1959; 20: 1028-1036.
44. Puschett JB: Diuretics, in Oparil S, Weber MA, (eds): Hypertension: A Companion to Brenner and Rector's the Kidney. WB Saunders Company, Philadelphia 2000, pp 584-590.
45. Clayton JA, Rodgers S, Blakey J, Avery A, Hall IP: Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2005; 61: 87-95.
46. Lithell HO: Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203-209.
47. Elliot W: Glucose and cholesterol elevations during thiazide therapy: intention to treat versus actual on-therapy experience. Am J Med 1995; 99: 216-219.
48. Wilcox CS: Metabolic and adverse effects of diuretics. Semin Nephrol 1999; 19: 557-568.
49. Inaba M, Noguchi Y, Yamamoto T, et al: Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens Res 2004; 27: 141-145.
50. Fukuda M, Kimura G: Pathophysiology of antihypertensive therapy with diuretics. Hypertens Res 2006; 29: 645-653.
51. Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gilbert GW, Oparil S: Fixed-dose combinations in the management of hypertension. Defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5: 17-22.
52. Palatini P: Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics. J Clin Invest 2005; 7: 96-101.
53. Julius PS, Kjeldsen PS, Weber PM, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
54. Suzuki S, Ohtomo M, Satoh Y, et al: Effect of manidipine and delapril on insulin sensitivity in type 2 diabetic patients with essential hypertension. Diabetes Res Clin Pract 1996; 33: 43-51.
55. Mugellini A, Preti P, Zoppi A, et al: Effect of delaprilmanidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 2004; 18: 687-691.